We are on a mission to improve the treatment of cancer, helping people live longer, healthier lives.

Fuzionaire Dx is a radiopharmaceutical company. Our HetSiFA® platform aims to unlock the power of theranostics to dramatically improve cancer care.

As a team of chemists, radiochemists, biophysicists, doctors, and entrepreneurs, including over a dozen additional scientists advancing our programs through special research collaborations, we are on a mission to develop accessible theranostics to fight cancer.

Our team

Fuzionaire Dx is led by a close-knit team of managers and world-class experts advising the company.

As we enter the world of precision medicine, Fuzionaire Diagnostics provides technology that could allow for many novel approaches in cancer therapy.

Douglas Scherr, MD Professor of Oncology and Clinical Director of Urologic Oncology Weill Medical College of Cornell University

Get in touch

If you are interested in learning more about our HetSiFA® platform, we want to hear from you.